Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Thrombin inhibitors inhelabo's pipeline

Aug. 9, 1996

RPR's enoxaparin reduces risk of DVT following hip replacement

Aug. 9, 1996

Hemaseel HMN phase I results announced

Aug. 9, 1996

Antithrombotic/antiallergic TxA2 synthase inhibitors from Terumo

July 26, 1996

Pharmacia & Upjohn introduces new dosage strength for Fragmin

July 26, 1996

D-HG: DIC/thrombosis treatment

July 26, 1996

BASF reports thrombin inhibitors

July 26, 1996

The Immune Response Corporation and Bayer to codevelop hemophilia A gene therapy

July 19, 1996

AlphaNine SD cleared by FDA

July 19, 1996

C85: TxB2 production/phosphoinositide breakdown inhibitor

July 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.